Company intelligence / Profile preview

E-Motion Medical

Ownership: Private
Development stage: Other

Overview

The E-Motion System has been tested on approximately 230 people across four clinical trials in Europe and Canada. The latest randomized double-blind trial with 155 patients demonstrated that the device promotes gastric motility, reduces aspiration risk, and speeds recovery. The system received CE Mark approval for commercialization in the European Union as of late 2018.

Therapeutic areas: GastroenterologyNeurology
Modalities: DeviceNon-pharmacological therapyElectrical stimulation therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on E-Motion Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E-Motion Medical.

Explore the full profile